Logo image
Defining MRI Superiority over CT for Colorectal and Neuroendocrine Liver Metastases
Journal article   Open access   Peer reviewed

Defining MRI Superiority over CT for Colorectal and Neuroendocrine Liver Metastases

Marc A. Attiyeh, Gautam K. Malhotra, Daneng Li, Saro B. Manoukian, Pejman M. Motarjem and Gagandeep Singh
Cancers, Vol.15(20)
2023

Abstract

gadobenic acid gadoterate meglumine gadoxetic acid adult aged Article cancer risk colorectal liver metastasis computer assisted tomography fatty liver female human interrater reliability liver metastasis major clinical study male middle aged neuroendocrine tumor nuclear magnetic resonance imaging radiologist recall bias treatment planning
Background: We compared CT and MRI for staging metastatic colorectal or neuroendocrine liver metastases (CRLMs and NELMs, respectively) to assess their impact on tumor burden. Methods: A prospectively maintained database was queried for patients who underwent both imaging modalities within 3 months, with two blinded radiologists (R1 and R2) independently assessing the images for liver lesions. To minimize recall bias, studies were grouped by modality, and were randomized and evaluated separately. Results: Our query yielded 76 patients (42 CRLMs; 34 NELMs) with low interrater variability (intraclass correlation coefficients: CT = 0.941, MRI = 0.975). For CRLMs, there were no significant differences in lesion number or size between CT and MRI. However, in NELMs, Eovist®-enhanced MRI detected more lesions (R1: 14.3 vs. 12.1, p = 0.02; R2: 14.4 vs. 12.4, p = 0.01) and smaller lesions (R1: 5.7 vs. 4.4, p = 0.03; R2: 4.8 vs. 2.9, p = 0.02) than CT. Conclusions: CT and MRI are equivalent for CRLMs, but for NELMs, MRI outperforms CT in detecting more and smaller lesions, potentially influencing treatment planning and surgery. © 2023 by the authors.
url
https://doi.org/10.3390/cancers15205109View
Published (Version of record) Open

Metrics

4 Record Views

Details

Logo image